Colin F Greineder

List of Publications by Year
in descending order

46 papers	1,549 citations	236925 25 h-index	315739 38 g-index
49 all docs	49 docs citations	49 times ranked	2209 citing authors

#	Article	IF	Citations
1	Early Convalescent Plasma for High-Risk Outpatients with Covid-19. New England Journal of Medicine, 2021, 385, 1951-1960.	27.0	177
2	Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the bloodâ€“brain barrier. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3405-3414.	7.1	97
3	Reduction of Nanoparticle Avidity Enhances the Selectivity of Vascular Targeting and PET Detection of Pulmonary Inflammation. ACS Nano, 2013, 7, 2461-2469.	14.6	94
4	Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. Journal of Controlled Release, 2014, 177, 34-41.	9.9	86
5	Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials, 2014, 35, 3708-3715.	11.4	80
6	Advanced drug delivery systems for antithrombotic agents. Blood, 2013, 122, 1565-1575.	1.4	78
7	Flexible Nanoparticles Reach Sterically Obscured Endothelial Targets Inaccessible to Rigid Nanoparticles. Advanced Materials, 2018, 30, e1802373.	21.0	73
8	Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. Journal of Controlled Release, 2012, 163, 161-169.	9.9	71
9	Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nature Nanotechnology, 2022, 17, 86-97.	31.5	57
10	Targeting therapeutics to endothelium: are we there yet?. Drug Delivery and Translational Research, 2018, 8, 883-902.	5.8	49
11	Vascular Immunotargeting to Endothelial Determinant ICAM-1 Enables Optimal Partnering of Recombinant scFv-Thrombomodulin Fusion with Endogenous Cofactor. PLoS ONE, 2013, 8, e80110.	2.5	48
12	Biocompatible coupling of therapeutic fusion proteins to human erythrocytes. Blood Advances, 2018, 2, 165-176.	5.2	42
13	Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opinion on Drug Delivery, 2015, 12, 239-261.	5.0	41
14	Vascular Targeting of Radiolabeled Liposomes with Bio-Orthogonally Conjugated Ligands: Single Chain Fragments Provide Higher Specificity than Antibodies. Bioconjugate Chemistry, 2018, 29, 3626-3637.	3.6	38
15	Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. Journal of Controlled Release, 2019, 301, 54-61.	9.9	36
16	Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1495-1506.	3.3	34
17	Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9. Scientific Reports, 2018, 8, 1760.	3.3	32
18	Ferritin Nanocages with Biologically Orthogonal Conjugation for Vascular Targeting and Imaging. Bioconjugate Chemistry, 2018, 29, 1209-1218.	3.6	32

#	Article	IF	Citations
19	Collaborative Enhancement of Antibody Binding to Distinct PECAM-1 Epitopes Modulates Endothelial Targeting. PLoS ONE, 2012, 7, e34958.	2.5	30
20	Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans. Journal of Controlled Release, 2016, 226, 229-237.	9.9	29
21	Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles. Bioconjugate Chemistry, 2016, 27, 628-637.	3.6	28
22	Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models. Current Hypertension Reports, 2011, 13, 436-441.	3.5	27
23	Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemiaâ€reperfusion injury. FASEB Journal, 2017, 31, 761-770.	0.5	27
24	ICAM-1â€“targeted thrombomodulin mitigates tissue factorâ€“driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Advances, 2017, 1, 1452-1465.	5.2	26
25	Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. Bioconjugate Chemistry, 2018, 29, 56-66.	3.6	26
26	Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect. FASEB Journal, 2015, 29, 3483-3492.	0.5	25
27	Targeting to Endothelial Cells Augments the Protective Effect of Novel Dual Bioactive Antioxidant/Anti-Inflammatory Nanoparticles. Molecular Pharmaceutics, 2014, 11, 2262-2270.	4.6	23
28	Collaborative Enhancement of Endothelial Targeting of Nanocarriers by Modulating Platelet-Endothelial Cell Adhesion Molecule-1/CD31 Epitope Engagement. ACS Nano, 2015, 9, 6785-6793.	14.6	22
29	Molecularly Engineered Nanobodies for Tunable Pharmacokinetics and Drug Delivery. Bioconjugate Chemistry, 2020, 31, 1144-1155.	3.6	20
30	Platelet Endothelial Cell Adhesion Molecule Targeted Oxidant-Resistant Mutant Thrombomodulin Fusion Protein with Enhanced Potency In Vitro and In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 339-345.	2.5	19
31	Targeted In Vivo Loading of Red Blood Cells Markedly Prolongs Nanocarrier Circulation. Bioconjugate Chemistry, 2022, 33, 1286-1294.	3.6	13
32	The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulmonary Circulation, 2018, 8, 1-18.	1.7	12
33	Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1. PLoS ONE, 2017, 12, e0169537.	2.5	11
34	In Vitro and In Silico Analysis of Annexin V Binding to Lymphocytes as a Biomarker in Emergency Department Sepsis Studies. Academic Emergency Medicine, 2007, 14, 763-771.	1.8	10
35	Systems approaches to design of targeted therapeutic delivery. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 253-265.	6.6	7
36	In Vitro and In Silico Analysis of Annexin V Binding to Lymphocytes as a Biomarker in Emergency Department Sepsis Studies. Academic Emergency Medicine, 2007, 14, 763-771.	1.8	5

#	Article	IF	Citations
37	Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies. Blood Advances, 2022, 6, 4645-4656.	5.2	5
38	A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain. PLoS ONE, 2021, 16, e0252558.	2.5	4
39	A library of Rhodamine6G-based pH-sensitive fluorescent probes with versatile in vivo and in vitro applications. RSC Chemical Biology, 2022, 3, 748-764.	4.1	3
40	Site-Specific Modification of Single-Chain Affinity Ligands for Fluorescence Labeling, Radiolabeling, and Bioconjugation. Methods in Molecular Biology, 2021, 2355, 163-173.	0.9	2
41	A Microfluidic Model of Microvascular Inflammation: Characterization and Testing of Endothelial-Targeted Therapeutics. Blood, 2015, 126, 3454-3454.	1.4	1
42	A Bioreactor for 3D In Vitro Modeling of the Mechanical Stimulation of Osteocytes. Frontiers in Bioengineering and Biotechnology, 2022, 10, 797542.	4.1	1
43	Shoulder Pseudodislocation Associated with Calcific Tendinitis/Bursitis and Diagnosed by Point of Care Ultrasound. Journal of Emergency Medicine, 2020, 58, 72-76.	0.7	0
44	Thrombomodulin Fusion Proteins Coupled to Human Erythrocytes Demonstrate Anti-Thrombotic and Anti-Inflammatory Activity. Blood, 2015, 126, 3493-3493.	1.4	0
45	Simultaneous Replacement of Endothelial Thrombomodulin and Plasma Protein C: A Novel Therapeutic Strategy for Sepsis-Induced Disseminated Intravascular Coagulation. Blood, 2016, 128, 2613-2613.	1.4	0
46	Coupling Therapeutics to Human Erythrocytes Demonstrates Target-Dependent Effects on Red Cell Physiology While Preserving Efficacy. Blood, 2016, 128, 701-701.	1.4	0